Form 4: ENANTA CSO Forfeits Shares for Tax Obligations

Enanta Pharmaceuticals' Chief Scientific Officer, Or Yat Sun, forfeited 753 shares of common stock to cover tax obligations related to a restricted stock unit settlement.

Summary

• Or Yat Sun, Chief Scientific Officer of ENANTA PHARMACEUTICALS INC (ENTA), reported a transaction on December 1, 2025.
• The transaction involved the disposition of 753 shares of ENTA common stock.
• These shares were forfeited to cover withholding taxes due to the settlement of a restricted stock unit (RSU) award.
• The RSU award was originally granted on November 19, 2021.
• The price per share for the forfeited stock was $14.12.
• Following this transaction, Or Yat Sun beneficially owns 373,782 shares of ENTA common stock directly.

Sentiment

Score: 5

Explanation: The transaction is neutral as it represents a routine, non-discretionary event related to tax obligations from a compensation award, rather than a discretionary sale or purchase reflecting a change in sentiment towards the company's prospects.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This is a routine insider transaction related to compensation and tax obligations, which is common across all industries, particularly for executives receiving equity-based compensation. It does not reflect broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: Minimal impact as this is a small, routine transaction for tax purposes and does not indicate a change in the executive's long-term holdings or company fundamentals.
• Employees: This transaction is a standard part of equity compensation, which is a common benefit for employees, particularly executives.

Key Dates

Keywords

ENANTA PHARMACEUTICALS, ENTA, Form 4, Insider Transaction, Restricted Stock Unit, RSU, Tax Withholding, Chief Scientific Officer